***Background.*** *Klebsiella pneumoniae* is an uncommon cause of community-acquired bacterial meningitis. The clinical and laboratory characteristics of community-acquired *K. pneumoniae* meningitis (CA-KPM) remain to be elucidated. In this study, we compared the clinical and laboratory features, and outcomes, of CA-KPM with those of community-acquired *Streptococcus pneumoniae* meningitis (CA-SPM).

***Methods.*** This multi-center, retrospective cohort study was performed at 8 general hospitals in the Republic of Korea. Using a clinical microbiology computerized database, all patients whose cerebrospinal fluid (CSF) cultures yielded *K. pneumoniae* or *S. pneumoniae* between January 1997 and March 2013 were identified. Adult patients with clinical meningitis were identified by detailed review of medical records.

***Results.*** A total of 83 patients, 27 with CA-KPM and 56 with CA-SPM, were included. The proportion of males (KPM, 55.6% vs SPM, 55.4%, *P* = 0.99) and median age (KPM, 59 year vs 59 year, *P* = 0.23) were not significantly different between the groups. Diabetes mellitus (KPM, 48.1% vs SPM, 21.4%; *P* = 0.01) and liver cirrhosis (KPM, 22.2% vs SPM, 5.4%; *P* = 0.05) were more common in the CA-KPM group. Although the profiles of CSF analyses did not differ significantly between the groups, comatose mentality was more frequent in the CA-KPM group (KPM, 40.7% vs SPM, 12.5%; *P* = 0.01). Septic shock (KPM, 44.4% vs SPM, 89%; *P* \< 0.001) and concomitant extrameningeal infection were also more common in the CA-KPM group (KPM, 37% vs SPM, 7.1%; *P* = 0.001). Vancomycin plus cefotaxime/ceftriaxone was the most frequently used initial empirical therapy (KPM, 74.1% vs SPM, 85.7%; *P* = 0.23) in both groups. However, 28-day mortality (KPM, 44.4% vs SPM, 10.7%; *P* \< 0.001) and in-hospital mortality (KPM, 51.9% vs SPM, 14.3%; *P* \< 0.001) were higher in the CA-KPM group.

***Conclusion.*** Diabetes mellitus and liver cirrhosis are more common in *K. pneumoniae* meningitis than *S. pneumoniae* meningitis, and the former is more likely to present severe manifestations and poor outcomes.
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